Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

Abstract:
Carigent Therapeutics, Inc., announced today that the National Cancer Institute of the National Institutes of Health has awarded Carigent a one-year, $153,000 Phase I Small Business Innovation Research (SBIR) grant to advance preclinical development of an innovative, long-circulating nanoparticle therapeutic that targets the specific molecular lesions in non-Hodgkin's lymphoma (NHL) patients.

Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-H

New Haven, CT | Posted on January 16th, 2008

Carigent's novel therapeutic approach is based on the company's proprietary technology for engineering biodegradable nanoparticles with exceptionally high-density surface modifications. The platform enables Carigent to design customized, multifunctional nanoscale carriers with the unique combined capability of:
Tethering multiple "functional groups" such as targeting ligands, diagnostic imaging agents, and polyethylene glycol (PEG) to the nanoparticle surface at previously unattainable densities, and Encapsulating single or combined therapeutic and/or diagnostic agents inside the nanoparticle for sustained, controlled release directly into targeted (i.e., diseased) tissues and cells.

"Non-Hodgkin's lymphoma has one of the fastest-growing incidence rates among cancers and is now the sixth most common cancer in the U.S.," said Seth Feuerstein, MD, JD, President and a co-founder of Carigent. "As we accelerate development of Carigent's engineered nanoparticle therapeutics to address unmet needs in cancer treatment, we are grateful for this financial support from the National Cancer Institute and the additional validation it provides Carigent's versatile nanoparticle delivery technology. The ability to modify particles for targeting as well as increased circulation time is what makes this an exciting project for the field."

####

About Carigent Therapeutics, Inc.
Carigent Therapeutics, Inc. is a biotechnology company developing and commercializing safer and more effective therapeutic and diagnostic products based on the companyís platform technology: Nanoparticles that enable delivery and controlled release of therapeutic and diagnostic agents into specific locations within the body and tissues. The companyís products and services are based on novel nanotechnology developed at Yale University that provides the unique capability of tethering agents for targeting, imaging, and increased circulation time at unprecedented densities to the surface of biodegradable polymer nanoparticles, resulting in drugs that bind to their targets more effectively, are delivered at a higher concentration to the desired location, and/or remain in the bloodstream longer than other nanotechnology-based drugs. The Carigent technology is broadly applicable across a wide variety of disease states and supports multiple types of targeting strategies and carrier designs for existing drugs as well as new drugs in development. Carigentís initial product development programs are focused on cancer therapeutics. In parallel, Carigent provides access to its nanoparticle drug delivery technology through collaborations and partnerships with pharmaceutical, biotechnology, and diagnostics companies. Carigent was established in 2007 and is based in New Haven, Connecticut.

For more information, please click here

Contacts:
Mary Moynihan
M2Friend Biocommunications
(802) 951-9600

Copyright © Carigent Therapeutics, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Superfast light source made from artificial atom April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

NREL theory establishes a path to high-performance 2-D semiconductor devices April 27th, 2016

Researchers create artificial protein to control assembly of buckyballs April 27th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Superfast light source made from artificial atom April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Grants/Awards/Scholarships/Gifts/Contests/Honors/Records

Brookhaven's Oleg Gang Named a Battelle 'Inventor of the Year': Recognized for work using DNA to guide and regulate the self-assembly of nanoparticles into clusters and arrays with controllable properties April 25th, 2016

Zip software can detect the quantum-classical boundary: Compression of experimental data reveals the presence of quantum correlations April 21st, 2016

Making electronics out of coal: Instead of burning up this complex hydrocarbon, let's make devices from it April 20th, 2016

Nano-magnets produce 3-dimensional images: Wide-view 3-dimensional holographic display composed of nano-magnetic pixels April 20th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic